Strongly enhanced levels of sclerostin during human fracture healing

Journal of Orthopaedic Research

Volumn 30, Issue 10, 2012, Pages 1549-1555

  Sarahrudi, Kambiz ^a   Thomas, Anita ^a   Albrecht, Christian ^a   Aharinejad, Seyedhossin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

fracture healing; human; non union; sclerostin; serum

Indexed keywords

SCLEROSTIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FRACTURE HEALING; FRACTURE NONUNION; HEMATOMA; HUMAN; LONG BONE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; FEMALE; FRACTURE HEALING; FRACTURES, UNUNITED; GENETIC MARKERS; HUMANS; MALE; REOPERATION;

EID: 84865490988     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22129     Document Type: Article

References (28)

1. Einhorn TA., 1998. The cell and molecular biology of fracture healing. Clin Orthop 355: S7-S21.
2. Einhorn TA., 1995. Enhancement of fracture healing. J Bone Joint Surg Am 77: 940-956.
3. Zimmermann G, Henle P, Küsswetter M, et al. 2005. TGF-β1 as marker of delayed fracture healing. Bone 36: 779-785. (Pubitemid 40616012)
4. Gerstenfeld LC, Cullinane DM, Barnes GL, et al. 2003. Fracture healing as post-natal development process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88: 373-384.
5. Chen Y, Whentstone HC, Lin AC, et al. 2007. Beta-catenin signaling plays a disparate role in different phases of fracture repaire; implications for therapy to improve bone healing. PLoS Med 4: e249.
6. Kim KB, Leucht P, Lam K, et al. Bone regeneration is regulated by wnt signalling. J Bone Miner Res 2007. 22: 1913-1923. (Pubitemid 351229308)
7. Leucht P, Kim JB, Helms JA., 2008. Beta-catenin-dependent Wnt signaling in mandibular bone regeneration. J Bone Joint Surg Am 90: 3-8. (Pubitemid 351329113)
8. Baron R, Rawadi G., 2007. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 7148: 2635-2643. (Pubitemid 46984775)
9. van Bezooijen RL, Bronckers AL, Gortzak RA, et al. 2009. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88: 569-574.
10. Rbling AG, Bellido T, Turner CH., 2006. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6: 354. (Pubitemid 46099713)
11. Bellido T, Ali AA, Gubrij I, et al. 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583. (Pubitemid 41446595)
12. Mirza FS, Padhi ID, Raisz LG, et al. 2010. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endicrinol Metab 95: 1991-1997.
13. Gaudio A, Pennisi P, Bratengeier C, et al. 2010. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95: 2248-3353.
14. Wehmeyer C, Stratis A, Pap T, et al. 2010. The Role of the WNT inhibitor sclerostin in rheumatoid arthritis. Ann Rheum Dis 69: A1-A76.
15. Sarahrudi K, Thomas A, Braunsteiner T, et al. 2009. VEGF serum concentrations in patients with long bone fractures; A comparison between impaired and normal fracture healing. J Orthop Res 27: 1293-1297.
16. Sarahrudi K, Mousavi M, Thomas A, et al. 2009. Elevated levels of macrophage colony-stimulating factor (M-CSF) in human fracture healing. J Orthop Res 28: 671-676.
17. Amrein K, Amrein S, Drexler C, et al. 2012. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97: 148-154.
18. Ardawi MS, Al-Sibiany AM, Bakhsh TM, et al. 2011. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int [Epub ahead of print].
19. García-Martín A, Rozas-Moreno P, Reyes-García R, et al. 2012. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97: 234-241.
20. Mödder UI, Hoey KA, Amin S, et al. 2011. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26: 373-379.
21. Winkler DG, Sutherland MK, Geoghegan JC, et al. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276. (Pubitemid 37522584)
22. Moustafa A, Sugiyama T, Prasad J, et al. 2012. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 4: 1225-1234.
23. Robling AG, Niziolek PJ, Baldridge LA, et al. 2008. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283: 5866-5875.
24. Li C, Ominsky MS, Tan HL, et al. 2011. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 49: 1178-1185.
25. Li X, Ominsky MS, Warnington KS, et al. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
26. Li X, Warmington KS, Niu QT, et al. 2010. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25: 2371-2380.
27. Tian X, Jee Ws, Li X, et al. 2011. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorptin in a hindlimb-immobilization rat model. Bone 48: 197-201.
28. Ominsky MS, Li C, Li X, et al. 2011. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 26: 1012-1021.